The Day After a Primary Endpoint

Affiliations

Free article

Editorial

David E Kandzari. JACC Cardiovasc Interv. 2018.

Free article

. 2018 Mar 12;11(5):470-472.

doi: 10.1016/j.jcin.2017.12.008.

¹ Piedmont Heart Institute, Atlanta, Georgia. Electronic address: david.kandzari@piedmont.org.

No abstract available

Keywords: clinical trials; drug-eluting stent(s).

Comment on

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C. Zocca P, et al. JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031. JACC Cardiovasc Interv. 2018. PMID: 29519378 Clinical Trial.